Abstract
Psoriatic arthritis (PsA), an inflammatory musculoskeletal disease associated with psoriasis, is a complex disease in terms of its clinical presentation, etiology, and pathogenesis. Musculoskeletal presentations include peripheral arthritis, spondylitis, enthesitis, and dactylitis. To learn about the course of and prognosis for such a complex disease, it is important to observe patients longitudinally so that all aspects of the disease are recognized. Several registries have been developed to evaluate the course of and prognosis for patients with PsA. Based on such registries, it has been shown that PsA is more severe than previously thought, and that progression of joint damage is related to joint inflammation. Such registries also have been used to determine genetic factors in PsA and to identify biomarkers for both susceptibility and expression of the disease. Drug registries also have been developed to document response to new therapies as well as the long-term adverse effects resulting from such therapies. It is hoped that an international effort currently on the way will further enhance the contribution of PsA patient registries to address the etiology, pathogenesis, and outcome of this complex disease.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance
Gladman DD, Ritchlin C, Helliwell PS. Psoriatic arthritis clinical registries and genomics. Ann Rheum Dis. 2005;64((Suppl II) ii):103–5.
Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum. 1973;3:55–78.
Moll JM, Wright V. Familial occurrence of psoriatic arthritis. Ann Rheum Dis. 1973;32:181–201.
Lambert JR, Wright V. Psoriatic spondylitis: a clinical and radiological description of the spine in psoriatic arthritis. Q J Med. 1977;46:411–25.
• Gladman DD, Chandran V. Observational cohorts studies: lessons learnt from the University of Toronto Psoriatic Arthritis Program. Rheumatol Online 2010;60:25–31. This paper describes the University of Toronto PsA program and the lessons learned from its registry.
• Nair RP, Duffin KC, Helms C, et al. The Collaborative Association Study of Psoriasis. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet 2009;41:199–204. This study included patients from several psoriasis registries and identified several novel genes in the susceptibility to psoriasis and PsA.
Jones SM, Armas JB, Cohen MG, et al. Psoriatic arthritis: outcome of disease subsets and relationship of joint disease to nail and skin disease. Br J Rheumatol. 1994;33:834–9.
Korendowych E, Dixey J, Cox B, et al. The Influence of the HLA-DRB1 rheumatoid arthritis shared epitope on the clinical characteristics and radiological outcome of psoriatic arthritis. J Rheumatol. 2003;30:96–101.
McHugh NJ, Balachrishnan C, Jones SM. Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology (Oxford). 2003;42:778–83.
Buckley C, Cavill C, Taylor G, et al. Mortality in psoriatic arthritis—a single-center study from the UK. J Rheumatol. 2010;37:2141214-4.
Wong K, Gladman DD, Husted J, et al. Mortality studies in psoriatic arthritis. Results from a single centre. I. Risk and causes of death. Arthritis Rheum. 1997;40:1868–72.
Ali Y, Tom BDM, Schentag CT, et al. Improved survival in psoriatic arthritis (PsA) with calendar time. Arthritis Rheum. 2007;56:2708–14.
Shbeeb M, Uramoto KM, Gibson LE, et al. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982–1991. J Rheumatol. 2000;27:1247–50.
Thumboo J, Uramoto K, Shbeeb MI, et al. Risk factors for the development of psoriatic arthritis: a population based nested case control study. J Rheumatol. 2002;29:757–62.
Wilson FC, Icen M, Crowson CS, et al. Time trends in epidemiology and characteristics of psoriatic arthritis over 3 decades: a population-based study. J Rheumatol. 2009;36:361–7.
Svensson B, Holmstrom G, Lindqvist U. Development and early experiences of a Swedish psoriatic arthritis register. Scand J Rheumatol. 2002;31:221–5.
• Lindqvist UR, Alenius GM, Husmark T, et al. The Swedish early psoriatic arthritis register—2-year followup: a comparison with early rheumatoid arthritis. J Rheumatol 2008;35:668–73. The Swedish early PsA registry includes patients with early PsA who are observed prospectively.
Gladman DD, Ng Tung Hing E, Schentag CT, Cook R. Remission in psoriatic arthritis. J Rheumatol. 2001;28:1045–8.
Kane D, Stafford L, Bresnihan B, FitzGerald O. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford). 2003;42:1460–8.
• Reddy SM, Anandarajah AP, Fisher MC, et al. Comparative analysis of disease activity measures, use of biologic agents, body mass index, radiographic features, and bone density in psoriatic arthritis and rheumatoid arthritis patients followed in a large U.S. disease registry. J Rheumatol 2010;37:2566–72. This is a cross-sectional study from a US-based registry. It includes a large number of patients with RA and PsA observed over time. However, the information collected is limited.
Gladman DD, Shuckett R, Russell ML, et al. Psoriatic arthritis—clinical and laboratory analysis of 220 patients. Quart J Med. 1987;62:127–41.
Gladman DD, Stafford-Brady F, Chang CH, et al. Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol. 1990;17:809–12.
Mader R, Gladman DD, Long J, Gough J, Farewell VT. Does injectable gold retard radiologic evidence of joint damage in psoriatic arthritis? Clin Investig Med. 1995;18:139–43.
Abu-Shakra M, Gladman DD, Thorne JC, et al. Longterm methotrexate therapy in psoriatic arthritis: clinical and radiologic outcome. J Rheumatol. 1995;22:241–5.
Rahman P, Gladman DD, Zhou Y, Cook RJ. The use of sulfasalazine in psoriatic arthritis: a clinic experience. J Rheumatol. 1998;25:1957–61.
Lee JCT, Gladman DD, Schentag CT, Cook RJ. The long-term use of azathioprine in patients with psoriatic arthritis. J Clin Rheumatol. 2001;7:160–5.
Eder L, Chandran V, Shen H, et al. Time and predictors of response to tumour necrosis factor-alpha blockers in psoriatic arthritis: an analysis of a longitudinal observational cohort. Rheumatology (Oxford). 2010;49:1361–6.
• Eder L, Chandran V, Ueng J, et al. Predictors of response to intra-articular steroid injection in psoriatic arthritis. Rheumatology (Oxford) 2010;49:1367–73. This is the first study to systematically assess the response to intra-articular injections among patients with PsA. Almost half of the patients responded. The presence of damage was detrimental to response. Migration inhibitory factor polymorphisms did not predict response but were associated with recurrence.
• Eder L, Chandran V, Shen H, et al. The incidence of arthritis in a prospective cohort of psoriasis patients. Arthritis Care Res (Hoboken) online 15/11/2010. This study demonstrated that the incidence of PsA among patients with psoriasis may be higher than what current figures indicate. This was a prospective cohort of patients with psoriasis observed according to the same standard protocol used in the PsA clinic.
Eder L, Loo T, Chandran V, et al. Environmental risk factors for psoriatic arthritis among patients with psoriasis: a case-control study. Arthritis Rheum. 2010;62 Suppl 10:S809.
Eder L, Chandran V, Pellett F, et al. The association of IL-13 polymorphism with psoriatic arthritis among psoriasis patients. Arthritis Rheum. 2010;62 Suppl 10:S830.
Eder L, Pellett F, Chandran V, et al. HLA-Cw*06 allele increases the duration of time between the onset of psoriasis and psoriatic arthritis. Arthritis Rheum. 2010;62 Suppl 10:S220.
• Glintborg B, Ostergaard M, Dreyer L, et al. Treatment response, drug survival and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor alpha therapy: results from the Danish nationwide DANBIO registry. Arthritis Rheum online 27/10/2010. PMID: 20981816. The use of biologics registries to determine drug survival and toxicity was demonstrated by this study from the Danish registry.
Carmona L, Descalzo MA, Ruiz-Montesinos D, et al. Safety and retention rate of off-label uses of TNF antagonists in rheumatic conditions: data from the Spanish registry BIOBADASER 2.0. Rheumatology. 2011;50:85–92.
Saad AA, Ashcroft DM, Watson KD, et al. Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. Arthritis Res Ther. 2009;11:R52.
Simard JF, Arkema EV, Sundstrom A, et al. Ten years with biologics: to whom do data on effectiveness and safety apply? Rheumatology (Oxford). 2011;50:204–13.
Aletaha D. Capturing real-life patient care in psoriatic arthritis and its risks: the challenge of analysing registry data. Arthritis Res Ther. 2009;11:112.
Brockbank J, Stein M, Schentag CT, Gladman DD. Dactylitis in psoriatic arthritis (PsA): a marker for disease severity? Ann Rheum Dis. 2005;62:188–90.
Queiro R, Torre JC, Belzunegui J, et al. Clinical features and predictive factors in psoriatic arthritis-related uveitis. Semin Arthritis Rheum. 2002;31:264–70.
Bond SJ, Farewell VT, Schentag CT, Gladman DD. Predictors for radiological damage in psoriatic arthritis. Results from a single centre. Ann Rheum Dis. 2007;66:370–6.
Gladman DD, Ang M, Su L, et al. Cardiovascular morbidity in psoriatic arthritis (PsA). Ann Rheum Dis. 2009;68:1131–5.
Rohekar S, Tom BD, Hassa A, et al. Malignancy in psoriatic arthritis. Arthritis Rheum. 2008;58:82–7.
• Chandran V, Cook RJ, Edwin J, et al. Soluble biomarkers differentiate patients with psoriatic arthritis from those with psoriasis without arthritis. Rheumatology (Oxford) 2010;49:1399–1405. The study demonstrated that there are biomarkers for susceptibility to psoriatic disease, some of which actually distinguish between patients with psoriasis alone and those with PsA.
Ritchlin CT, Haas-Smith SA, Li P, et al. Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest. 2003;111:821–31.
Chiu YG, Shanmugarajah S, Oanpento B, et al. DC-STAMP (dendritic cell specific transmembrane protein), a potential biomarker to predict the risk of psoriasis patients in developing psoriatic arthritis. Arthritis Rheum. 2101;62 Suppl 10:S217.
Chandran V, Raychaudhuri SP. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun. 2010;34:J314.
Ellinghaus E, Ellinghaus D, Stuart PE, et al. Genome-wide association study reveals association of psoriasis with TRAF3IP2. Nat Genet. 2010;42:991–5.
• Stuart PE, Nair RP, Ellinghaus E, et al. Genome-wide association analysis identifies three psoriasis susceptibility loci. Nat Genet 2010;42:1000–4. There are now two large genome-wide association studies that identified patients with PsA. A meta-analysis of those studies identified three new psoriasis and PsA susceptibility loci.
Askling J. Malignancy and rheumatoid arthritis. Curr Rheumatol Rep. 2007;9:421–6.
Toloza SMA, Valle-Oñate R, Espinoza LR. Psoriatic arthritis in South and Central America. Curr Rheum Rep 2011 (in press)
Acknowledgments
Dr. Chandran has been supported by a Canadian Institutes of Health Research/Clinical Research Initiative Fellowship, the Krembil Foundation, and the CIHR-NET grant on psoriasis and psoriatic arthritis.
Disclosure
Dr. Gladman has served as a consultant for Amgen, Centocor Ortho Biotech, Bristol-Myers Squibb, Merck & Co., Pfizer, and UCB.
Dr. Chandran has served as a consultant for Amgen and Pfizer; has received royalties from Oxford University Press; and has received payment for development of educational presentations, including service on speakers’ bureaus, from Wyeth/Pfizer, Abbott Laboratories, Schering-Plough/Merck & Co., and Bristol-Myers Squibb.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gladman, D.D., Chandran, V. Review of Clinical Registries of Psoriatic Arthritis: Lessons Learned? Value for the Future?. Curr Rheumatol Rep 13, 346–352 (2011). https://doi.org/10.1007/s11926-011-0182-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11926-011-0182-x